secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178463
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru Q3 net loss narrows to $0.50/sh; enobosarm Phase 2b data show lean mass preservation
--------------------------------------------------------------------------------

- Net loss from continuing ops $7.3M ($0.50/sh) vs $10.3M ($0.71/sh) in Q3 2024.
- R&D expense $3.0M, down from $4.8M; SG&A $5.0M, down from $5.8M.
- Cash $15.0M at June 30, 2025 vs $24.9M at Sep 30, 2024; burn funds clinical programs.
- Phase 2b QUALITY: enobosarm 3mg + semaglutide preserved 100% lean mass (p<0.001) and increased fat loss 12% vs semaglutide alone.
- Maintenance Extension: enobosarm 3mg monotherapy reduced weight regain by 46% after semaglutide discontinuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/0001193125-25-178463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/d59822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer